[accessibility][main content][search][section menu][right column][footer]

Our track record speaks for itself...

In the eye of the storm

26.06.2007 - Trademark World
Lucy Kilshaw of CMS Cameron McKenna discusses the ECJ's view on 'relevant public' when assessing the likelihood of confusion.

In a dispute about the possible conflict between the marks TRIVASTAN and TRAVATAN for eye treatment in the pharmaceutical market, the ECJ agreed with the Court of First Instance (CFI) and the Advocate General in finding a likelihood of confusion. However, the Court's view differed from the Advocate General on the definition of the "relevant public" applicable to prescription-only pharmaceutical products when assessing the likelihood of confusion.

Please click here to read the full article.

For further information, please contact:


	Lucy Kilshaw London +44 (0) 20 7367 2044

CMS Cameron McKenna LLP is a limited liability partnership registered in England and Wales. It is able to provide international legal services to clients utilising, where appropriate, the services of its associated international offices and/or member firms of the CMS organisation. The associated international offices of CMS Cameron McKenna LLP are separate and distinct from it.

CMS Cameron McKenna LLP and its associated offices are members of the CMS organisation of major independent European law firms. The CMS organisation firms are legal entities which are separate and distinct from CMS Cameron McKenna LLP and its associated international offices.

Law-Now information is for general purposes and guidance only and does not purport to constitute legal or professional advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

Law-Now is a registered trademark.